{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:09:47Z","timestamp":1790633387983,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Helicobacter pylori infection may persist after multiple eradication treatments. The aim of this study was to evaluate the efficacy and safety of a furazolidone-based rescue regimen in hyper-refractory patients. A unicentre, prospective study was designed. Patients in whom five or more treatments had consecutively failed were included. All patients had previously received bismuth and key antibiotics, such as amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and rifabutin, and had positive H. pylori culture, demonstrating resistance to clarithromycin, metronidazole, and levofloxacin. A quadruple regimen with furazolidone (200 mg), amoxicillin (1 g), bismuth (240 mg), and esomeprazole (40 mg) was prescribed twice a day for 14 days. Eradication was confirmed by the stool antigen test. Compliance was determined through questioning, and adverse effects using a questionnaire. Eight patients (mean age 56 years, 63% men, 38% peptic ulcer disease, 12% gastric cancer precursor lesions, and 50% functional dyspepsia) were included. Per-protocol and intention-to-treat eradication rates were 63%. Compliance was 100%. Adverse effects were reported in two (25%) patients, and all were mild. Even after five or more previous H. pylori eradication failures, and a multi-resistant infection, rescue treatment with furazolidone may be effective in approximately two-thirds of the cases, constituting a valid strategy after multiple previous eradication failures with key antibiotics such as clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin.<\/jats:p>","DOI":"10.3390\/antibiotics10091028","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T22:12:22Z","timestamp":1629843142000},"page":"1028","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7998-8327","authenticated-orcid":false,"given":"Elena","family":"Resina","sequence":"first","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Gastroenterology Unit, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid (UAM), 28049 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Gastroenterology Unit, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid (UAM), 28049 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMcp1710945","article-title":"Helicobacter pylori Infection","volume":"380","author":"Crowe","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pero, R., Brancaccio, M., Laneri, S., Biasi, M.G., Lombardo, B., and Scudiero, O. (2019). A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins. Biomolecules, 9.","DOI":"10.3390\/biom9060237"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Angrisano, T., Pero, R., Brancaccio, M., Coretti, L., Florio, E., Pezone, A., Calabr\u00f2, V., Falco, G., Keller, S., and Lembo, F. (2016). Cyclical DNA Methylation and Histone Changes Are Induced by LPS to Activate COX-2 in Human Intestinal Epithelial Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156671"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0859-1883","article-title":"Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019","volume":"51","author":"Libanio","year":"2019","journal-title":"Endoscopy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.gastrohep.2020.08.004","article-title":"Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP","volume":"44","author":"Cubiella","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.gastrohep.2016.05.003","article-title":"IV Spanish Consensus Conference on Helicobacter pylori infection treatment","volume":"39","author":"Gisbert","year":"2016","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1756284820968736","DOI":"10.1177\/1756284820968736","article-title":"Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review","volume":"13","author":"Gisbert","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gisbert, J.P. (2020). Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens, 10.","DOI":"10.3390\/pathogens10010015"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1756284820937115","DOI":"10.1177\/1756284820937115","article-title":"High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: A systematic review with meta-analysis","volume":"13","author":"Zhu","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/1319-3767.91729","article-title":"Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis","volume":"18","author":"Zullo","year":"2012","journal-title":"Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1746.1992.tb01034.x","article-title":"Treatment of peptic ulcer disease with furazolidone","volume":"7","author":"Zheng","year":"1992","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.gastrohep.2010.10.013","article-title":"Rescue therapy after Helicobacter pylori eradication failure","volume":"34","author":"Gisbert","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3748\/wjg.15.860","article-title":"Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori","volume":"15","author":"Cheng","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.3748\/wjg.v24.i40.4596","article-title":"Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication","volume":"24","author":"Zhang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_16","first-page":"313","article-title":"In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate","volume":"18","author":"Domingo","year":"2005","journal-title":"Rev. Esp. Quimioter. Publ. Of. Soc. Esp. Quimioter."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12591","DOI":"10.1111\/hel.12591","article-title":"Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice","volume":"24","author":"Song","year":"2019","journal-title":"Helicobacter"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1523-5378.2012.00946.x","article-title":"A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure","volume":"17","author":"Fakheri","year":"2012","journal-title":"Helicobacter"},{"key":"ref_19","first-page":"Pi105","article-title":"The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy","volume":"9","author":"Mirmomen","year":"2003","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_20","first-page":"1134","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori: Lessons from China","volume":"25","author":"Lu","year":"2013","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pero, R., Angrisano, T., Brancaccio, M., Falanga, A., Lombardi, L., Natale, F., Laneri, S., Lombardo, B., Galdiero, S., and Scudiero, O. (2019). Beta-defensins and analogs in Helicobacter pylori infections: mRNA expression levels, DNA methylation, and antibacterial activity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222295"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/17512433.2019.1654858","article-title":"Multidrug resistance in Helicobacter pylori: Current state and future directions","volume":"12","author":"Boyanova","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e12557","DOI":"10.1111\/hel.12557","article-title":"Helicobacter pylori antimicrobial resistance during a 5-year period (2013\u20132017) in northern Spain and its relationship with the eradication therapies","volume":"24","author":"Cosme","year":"2019","journal-title":"Helicobacter"},{"key":"ref_26","unstructured":"Bujanda, L., Nyssen, O., Cosme, A., Bordin, D., Tepe\u0161, B., Perez-Aisa, A., Vaira, D., Caldas, M., Castro-Fernandez, M., and Lerang, F. (2020, January 3\u20135). Helicobacter pylori antibiotic resistance: Data from the european registry on H. pylori management (Hp-EuReg). Proceedings of the United European Gastroenterology Journal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","article-title":"Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17474124.2021.1826306","article-title":"The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection","volume":"15","author":"Yun","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/j.1572-0241.2006.00668.x","article-title":"Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: A systematic review and meta-analysis","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_30","unstructured":"CADTH Rapid Response Reports (2015). Stool Antigen Tests for Helicobacter pylori Infection: A Review of Clinical and Cost-Effectiveness and Guidelines, Canadian Agency for Drugs and Technologies in Health Copyright\u00a9."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e12468","DOI":"10.1111\/hel.12468","article-title":"Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis","volume":"23","author":"Zhuge","year":"2018","journal-title":"Helicobacter"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1440-1746.2007.05082.x","article-title":"Nitrofuran-based regimens for the eradication of Helicobacter pylori infection","volume":"22","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1319-3767.91724","article-title":"Furazolidone in Helicobacter pylori therapy: Misunderstood and often unfairly maligned drug told in a story of French bread","volume":"18","author":"Graham","year":"2012","journal-title":"Saudi J. Gastroenterol. Off. J. Saudi Gastroenterol. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.14309\/ajg.0000000000001246","article-title":"Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)","volume":"116","author":"Nyssen","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7189519","DOI":"10.1155\/2020\/7189519","article-title":"Clinical Performance of the Automated LIAISON\u00ae Meridian H. pylori SA Stool Antigen Test","volume":"2020","author":"Opekun","year":"2020","journal-title":"BioMed Res. Int."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/9\/1028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:50:21Z","timestamp":1760165421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/9\/1028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["antibiotics10091028"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10091028","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]}}}